PMID- 19675743
OWN - NLM
STAT- MEDLINE
DCOM- 20091217
LR  - 20211020
IS  - 1612-3174 (Electronic)
IS  - 1612-3174 (Linking)
VI  - 7
DP  - 2009 May 6
TI  - Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in 
      Egyptian patients with breast cancer.
PG  - Doc03
LID - 10.3205/000062 [doi]
LID - Doc03
AB  - Breast cancer is a leading cause of cancer-related deaths in women worldwide. The 
      clinical course of this disease is highly variable and clinicians continuously 
      search for prognostic parameters that can accurately predict prognosis, and 
      indicate a suitable adjuvant therapy for each patient. Amplification of the two 
      oncogenes HER-2/neu and c-myc and inactivation of the tumor suppressor gene p53 
      are frequently encountered in breast carcinomas. The purpose of this study was to 
      use the fluorescence in situ hybridization (FISH) for the assessment of HER-2/neu 
      and c-myc amplification and p53 inactivation and to relate these molecular 
      markers with the commonly used clinical and pathological factors. The study was 
      conducted on 34 tissue samples obtained from 33 females and 1 male with breast 
      carcinomas and 17 samples obtained from 16 females and 1 male with benign breast 
      lesions. Results revealed that the level of HER-2/neu, c-myc and p53 in the 
      malignant group was significantly increased as compared to the benign group. On 
      relating the level of the molecular markers to clinicopathological factors, p53 
      was significantly associated with increased patient's age. The sensitivity of the 
      investigated markers significantly increased with larger tumor size. Concerning 
      tumor grade, HER-2/neu and p53 showed a significant increase in low-grade tumors 
      whereas c-myc showed a highly significant increase in high-grade tumors. With 
      regard to disease staging, HER-2/neu and c-myc were the only markers that showed 
      significant increase at late stages of disease. p53 and HER-2/neu were 
      significantly associated with positive lymph nodal status. A significant 
      correlation was obtained between the levels of the three biomarkers to each 
      other. Conclusively, the combination of HER-2/neu, c-myc and p53 can stratify 
      patients into different risk groups.
FAU - Ismail, Manal F
AU  - Ismail MF
AD  - Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
FAU - Aly, Magdy Sayed
AU  - Aly MS
FAU - Khaled, Hussein M
AU  - Khaled HM
FAU - Mohamed, Hanaa M
AU  - Mohamed HM
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20090506
PL  - Germany
TA  - Ger Med Sci
JT  - German medical science : GMS e-journal
JID - 101227686
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/analysis
MH  - Biopsy
MH  - Breast Neoplasms/diagnosis/epidemiology/*genetics
MH  - Breast Neoplasms, Male/diagnosis/epidemiology/genetics
MH  - Egypt/epidemiology
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging/methods
MH  - Nucleic Acid Amplification Techniques/methods
MH  - Prevalence
MH  - Proto-Oncogene Proteins c-myc/*analysis/genetics
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Tumor Suppressor Protein p53/*analysis/genetics
MH  - Young Adult
PMC - PMC2716551
OTO - NOTNLM
OT  - HER-2/neu
OT  - breast cancer
OT  - c-myc
OT  - fluorescent in situ hybridization (FISH)
OT  - genetic alterations
OT  - p53
EDAT- 2009/08/14 09:00
MHDA- 2009/12/18 06:00
PMCR- 2009/05/06
CRDT- 2009/08/14 09:00
PHST- 2009/03/04 00:00 [received]
PHST- 2009/04/27 00:00 [revised]
PHST- 2009/08/14 09:00 [entrez]
PHST- 2009/08/14 09:00 [pubmed]
PHST- 2009/12/18 06:00 [medline]
PHST- 2009/05/06 00:00 [pmc-release]
AID - 000062 [pii]
AID - 10.3205/000062 [doi]
PST - epublish
SO  - Ger Med Sci. 2009 May 6;7:Doc03. doi: 10.3205/000062.